Bioventus Overview
- Year Founded
-
2012
- Status
-
Public
- Employees
-
960
- Stock Symbol
-
BVS
- Investments
-
12
- Share Price
-
$9.88
- (As of Friday Closing)
Bioventus General Information
Description
Bioventus Inc is a medical device company focused on developing and commercializing products to relieve pain and address musculoskeletal conditions. The company operates through two reporting segments, U.S. and International, and its product portfolio is organized into three main business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies, offering products such as hyaluronic acid injections for osteoarthritis, peripheral nerve stimulation devices, bone graft substitutes, and ultrasound-based fracture healing therapies.
Contact Information
Website
www.bioventus.comCorporate Office
- 4721 Emperor Boulevard
- Suite 100
- Durham, NC 27703
- United States
Corporate Office
- 4721 Emperor Boulevard
- Suite 100
- Durham, NC 27703
- United States
Bioventus Stock Performance
As of 20-Nov-2026, Bioventus’s stock price is $9.88. Its current market cap is $677M with 68.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $9.88 | $9.95 | $6.47 - $15.89 | $677M | 68.5M | 540K | $0.85 |
Bioventus Financials Summary
As of 30-Sep-2026, Bioventus has a trailing 12-month revenue of $586M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,199,100 | 819,884 | 1,064,970 | 748,547 |
| Revenue | 585,639 | 568,087 | 573,280 | 512,345 |
| EBITDA | 101,743 | 99,206 | 36,005 | (23,070) |
| Net Income | 57,296 | 22,732 | (36,125) | (156,230) |
| Total Assets | 673,430 | 683,559 | 727,956 | 810,910 |
| Total Debt | 229,827 | 293,951 | 335,627 | 394,846 |
Bioventus Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Bioventus Comparisons
Industry
Financing
Details
Bioventus Competitors (20)
One of Bioventus’s 20 competitors is Orthofix Medical, a Formerly PE-Backed company based in Lewisville, TX.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orthofix Medical | Formerly PE-Backed | Lewisville, TX | ||||
| Mölnlycke Health Care | Private Equity-Backed | Mölndal, Sweden | ||||
| Performance Health Holding | Private Equity-Backed | Downers Grove, IL | ||||
| MicroPort Scientific | Formerly VC-backed | Shanghai, China | ||||
| Exactech | Formerly PE-Backed | Gainesville, FL |
Bioventus Patents
Bioventus Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202511799-D0 | Wound filler | Pending | 21-Jul-2025 | ||
| GB-202510930-D0 | Dressing status monitoring and exudate fill determination | Inactive | 07-Jul-2025 | ||
| GB-202507025-D0 | Conformable and separable printed circuit board assemblies for negative pressure wound therapy system | Pending | 08-May-2025 | ||
| GB-202502322-D0 | Dressing fixture and method | Pending | 17-Feb-2025 | ||
| GB-202414397-D0 | Negative and/or positive pressure therapy devices and methods with natural language interfaces | Pending | 01-Oct-2024 |
Bioventus Signals
Bioventus Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Bioventus Investments & Acquisitions (12)
Bioventus’s most recent deal was a Merger/Acquisition with CartiHeal for . The deal was made on 12-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CartiHeal | 12-Jul-2022 | Merger/Acquisition | Therapeutic Devices | ||
| Misonix | 29-Oct-2021 | Merger/Acquisition | Surgical Devices | ||
| Trice Medical | 25-Aug-2021 | Later Stage VC | Surgical Devices | ||
| Vaporox | 16-Aug-2021 | Later Stage VC | Therapeutic Devices | ||
| Bioness | 30-Mar-2021 | Merger/Acquisition | Therapeutic Devices |
Bioventus ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
31.17 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Devices
Subindustry
of 209
Rank
Percentile
Bioventus Exits (6)
Bioventus’s most recent exit was on 12-Jul-2022 from CartiHeal. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| CartiHeal | 12-Jul-2022 | Completed |
|
||
| Bioness | 30-Mar-2021 | Completed |
|
||
| CartiHeal | 16-Jul-2020 | Completed |
|
||
| CartiHeal | 31-Jan-2018 | Completed |
|
||
| BMP Development Program | 01-Jul-2013 | Buyout/LBO | Completed |
|
Bioventus Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Perseus Intermediate | Durham, NC | 2021 |
Bioventus FAQs
-
When was Bioventus founded?
Bioventus was founded in 2012.
-
Where is Bioventus headquartered?
Bioventus is headquartered in Durham, NC.
-
What is the size of Bioventus?
Bioventus has 960 total employees.
-
What industry is Bioventus in?
Bioventus’s primary industry is Diagnostic Equipment.
-
Is Bioventus a private or public company?
Bioventus is a Public company.
-
What is Bioventus’s stock symbol?
The ticker symbol for Bioventus is BVS.
-
What is the current stock price of Bioventus?
As of 20-Nov-2026 the stock price of Bioventus is $9.88.
-
What is the current market cap of Bioventus?
The current market capitalization of Bioventus is $677M.
-
What is Bioventus’s current revenue?
The trailing twelve month revenue for Bioventus is $586M.
-
Who are Bioventus’s competitors?
Orthofix Medical, Mölnlycke Health Care, Performance Health Holding, MicroPort Scientific, and Exactech are some of the 20 competitors of Bioventus.
-
What is Bioventus’s annual earnings per share (EPS)?
Bioventus’s EPS for 12 months was $0.85.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process